Medincell Says Teva Raises 2026 UZEDY Sales Forecast to $290 Million-$310 Million

• Medincell partner Teva raised its 2026 UZEDY sales forecast to $290 million–$310 million from $270 million–$290 million.
• Third-quarter US net sales reached $85 million, up 96% year over year.
• Nine-month US net sales totaled $225 million, exceeding full-year 2025 sales of $191 million.
• Medincell receives mid- to high-single-digit royalties on net sales and is eligible for $105 million in sales-based milestone payments.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Medincell SA published the original content used to generate this news brief via Business Wire (Ref. ID: 20261103131431) on November 03, 2026, and is solely responsible for the information contained therein.